Abstract
Purpose
Ovarian function is important for optimizing endocrine treatment in patients with hormone receptor-positive (HR+) early breast cancer (eBC). The aim of the study was to determine whether patients’ pretreatment levels of anti-Mullerian hormone (AMH) were associated with menses status after chemotherapy and to build a predictive nomogram model for amenorrhea in women with HR+ eBC.
Methods
Between August 2013 and December 2014, 120 premenopausal patients with HR+ eBC were included retrospectively. The associations among age, prechemotherapy levels of AMH, follicle-stimulating hormone (FSH),and estradiol (E2) and the 2-year postchemotherapy menses status were analyzed. We determined the cutoff values of hormone levels by using the biostatistical tool (Cutoff Finder). A novel nomogram was established to predict the 2-year amenorrhea status based on the logistic analysis. Concordance index (C-index) was used to validate the capacity.
Results
One hundred nine women (90.8%) experienced amenorrhea after chemotherapy. AMH < 0.965 ng/ml predicted amenorrhea at 2 years (AUC 0.84, sensitivity 74% and specificity 81.8%), independent of age. The predictive nomogram based on age and pretreatment AMH and FSH levels was developed to predict the probability of 2-year postchemotherapy amenorrhea with a C-index of 0.88 (95% CI 0.84–0.91).
Conclusions
In premenopausal patients with HR+ eBC, prechemotherapy AMH concentration was associated with the patient’s 2-year amenorrhea status, independent of age. The nomogram model based on age and pretreatment AMH and FSH levels accurately predicted the 2-year amenorrhea status.
Similar content being viewed by others
References
Xue C, Wang X, Peng R, Shi Y, Qin T, Liu D, Teng X, Wang S, Zhang L, Yuan Z (2012) Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci 103(9):1679–1687. https://doi.org/10.1111/j.1349-7006.2012.02339.x
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, Text, Investigators S, International Breast Cancer Study G (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118. https://doi.org/10.1056/NEJMoa1404037
Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, Investigators S, International Breast Cancer Study G (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446. https://doi.org/10.1056/NEJMoa1412379
Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF (2017) The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 87:58–64. https://doi.org/10.1016/j.ejca.2017.10.001
Xue C, Peng R, Cao Y, Wang S, Shi Y, An X, Xu F, Yuan Z (2016) Ovarian function, not age, predicts the benefit from ovarian suppression or ablation for premenopausal women with breast cancer. PLoS ONE 11(2):e0148849. https://doi.org/10.1371/journal.pone.0148849
Burstein HJ, Winer EP (2000) Primary care for survivors of breast cancer. N Engl J Med 343(15):1086–1094. https://doi.org/10.1056/NEJM200010123431506
Krekow LK, Hellerstedt BA, Collea RP, Papish S, Diggikar SM, Resta R, Vukelja SJ, Holmes FA, Reddy PK, Asmar L, Wang Y, Fox PS, Peck SR, O’Shaughnessy J (2016) Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40 s treated with Letrozole. J Clin Oncol 34(14):1594–1600. https://doi.org/10.1200/JCO.2015.62.2985
Su HC, Haunschild C, Chung K, Komrokian S, Boles S, Sammel MD, DeMichele A (2014) Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer 120(23):3691–3698. https://doi.org/10.1002/cncr.28942
Anderson RA, Rosendahl M, Kelsey TW, Cameron DA (2013) Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 49(16):3404–3411. https://doi.org/10.1016/j.ejca.2013.07.014
Broer SL, Broekmans FJ, Laven JS, Fauser BC (2014) Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 20(5):688–701. https://doi.org/10.1093/humupd/dmu020
Anderson RA, Cameron DA (2011) Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 96(5):1336–1343. https://doi.org/10.1210/jc.2010-2582
Henry NL, **a R, Schott AF, McConnell D, Banerjee M, Hayes DF (2014) Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 19(1):68–74. https://doi.org/10.1634/theoncologist.2013-0145
Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew K, Lobo RA, Hershman DL (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116(9):2099–2105. https://doi.org/10.1002/cncr.25037
Yang Y, Zhang YJ, Zhu Y, Cao JZ, Yuan ZY, Xu LM, Wu JX, Wang W, Wu T, Lu B, Zhu SY, Qian LT, Zhang FQ, Hou XR, Liu QF, Li YX (2015) Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia 29(7):1571–1577. https://doi.org/10.1038/leu.2015.44
Goldhirsch A, Gelber RD, Castiglione M (1990) The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1(3):183–188
Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332(14):901–906. https://doi.org/10.1056/NEJM199504063321401
Folkerd EJ, Lonning PE, Dowsett M (2014) Interpreting plasma estrogen levels in breast cancer: caution needed. J Clin Oncol 32(14):1396–1400. https://doi.org/10.1200/JCO.2013.53.9411
Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7(12):e51862. https://doi.org/10.1371/journal.pone.0051862
Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W, Korean Breast Cancer S (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25(17):2360–2368. https://doi.org/10.1200/JCO.2006.10.3754
Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA (2013) Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol 31(31):3914–3919. https://doi.org/10.1200/JCO.2012.47.7893
Davidson NE, O’Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD (2005) Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23(25):5973–5982. https://doi.org/10.1200/JCO.2005.05.551
Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, Gosiengfiao Y, Gracia CR (2013) Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 99(2):477–483. https://doi.org/10.1016/j.fertnstert.2012.09.039
Funding
This study was supported by Grants from the International Collaboration Foundation of Science and Technology Planning Project of Guangdong Province of China (2016A050502015), the National Natural Science Foundation of China (81773279), and the Fundamental Research Funds for the Central Universities (17ykzd33). The funder had no role in study design, analysis, or decision to publish.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
It was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Xue, C., Wei, W., Sun, P. et al. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Res Treat 173, 619–628 (2019). https://doi.org/10.1007/s10549-018-4997-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-018-4997-2